Hemeo is delighted to announce that it has signed a Collaborative Research Agreement with University of Florida Health. This agreement lays the ground for the sharing of targeted data and the research of optimal coagulation management for patients undergoing cardiac surgery with cardiopulmonary bypass.
Dr Bruce Spiess MD FAHA, Professor Of Anesthesiology and Associate Chair for Research at University Of Florida Health commented: “Coagulation in cardiac surgery is an example of biological complexity baffling many who practice medicine. Artificial intelligence systems could provide an answer to assist the guidance of therapy for the prevention and treatment of bleeding after heart surgery, I am excited to see a first foray into creating computer applications to tackle a problem that vexes many”. Remi Corlin, CEO Hemeo added “This agreement is an important milestone in the deployment of our research strategy. Hemeo has a proprietary coagulation model designed to build a digital twin of the patient’s coagulation profile. Applying our model to such a specific pool of clinical data will allow us to develop, verify and eventually validate specific algorithms to predict risks of bleeding in cardiac surgery, providing clinicians with vital information to design early and personalised therapies for their patients to minimise post-operative bleeding, leading to improved patient outcomes”
In the months to come, Hemeo plans to research, validate and deploy its technology across a diverse field of clinical applications where coagulopathies continue to severely impact patients, working with leading European and US academic hospitals. Hemeo is a Dutch healthtech venture whose mission is to revolutionise coagulation management with data.
Two publications have just been released, on Hemeo’s research: “Assessing the risk of DIC development in sepsis and SIRS” and “Real-world data on the effect of anticoagulants to prevent or treat DIC.” These publications are now available on our website, on the Resources page.
We are proud to be part of this well known event and get the opportunity to share our story with a broader audience. We are gaining momentum across different communities, investors, clinicians, researchers.
Europe is a great ecosystem for innovation in healthtech, and in medtech in particular, with active regional innovation hubs, companies used to cooperate with stakeholders, excellent universities and research institutes and public and private investors. The Reflection Paper on Innovation in Medtech, released by MedTech Europe in Nov 2020 has highlighted the value of bridging the gap between innovative start-ups and global companies More can be done in strengthening their cooperation. Three success stories will be presented in tandem talks between corporates and start-ups to illustrate the ups and downs of such cooperation.
Next to the presentation of the Hemeo case by CEO Remi Corlin, two other speakers will present their case: Mark Bloemendaal, CEO of Angiogenesis Analytics, and Ilker Soydan, CEO of EchoGuide. The session at the MedTech Forum will be moderated by Nina Rijnders, responsible for Corporate Partnerships at NLC, The European Healthech Venture Builder.
more info: https://www.themedtechforum.eu/
We are delighted to announce that Hemeo received seed funding from the Momentum fund. This 2.2M€ fund is designed to provide private investors the opportunity to invest in startups at an early stage while spreading the risk across a portfolio of ventures.
With this funding, Hemeo is able to initiate work with clinicians and hospitals to design our very first application. We are enthused by the strong support received from the clinician community and the ongoing collaboration with 5 leading academic hospitals.